Medigus: Successful Three-Year Follow-Up Data of the SRS™ Pivotal Study in Indiana University Will be Presented at the Digestive Disease Week in Orlando

OMER, Israel, May 16, 2013 /PRNewswire/ --

Medigus Ltd. (TASE:MDGS), a leading medical device company dedicated to the development of innovative endoscopic procedures and technologies, will be presenting the successful three year follow-up data of the SRS™ pivotal study at the Digestive Disease Week in Orlando on May 18-21^st 2013.

     (Logo: http://photos.prnewswire.com/prnh/20130313/601331 )

The study that was conducted in Indiana University, a leading U.S medical center, clearly indicates that the majority of patients treated by the endoscopic system SRS™ were able to stop taking daily PPl (drugs that have a long-lasting reduction effect of gastric acid production) in the third year post the procedure.

This three year study is presented shortly after five-year follow-up results of a pilot study of the SRS™ endoscopic system for the treatment of Gastroesophageal Reflux Disease (GERD). The pilot study had been conducted at the Deenanath Mangeshkar Hospital and Research Center in Pune, India in 2007.

As reported by the lead investigator of the pilot study Dr. Amol Bapaye, the five-year follow-up results are similar to those produced by a laparoscopic-surgical procedure for the treatment of GERD in the same timeframe.

The endoscopic system SRS™ performs a minimally-invasive treatment of Gastroesophageal Reflux Disease (GERD), one of the most common chronic diseases globally. The system which includes a disposable surgical endoscope, performs an anterior fundoplication in lieu of the current surgical procedure, without incisions and opening the abdominal cavity.

The SRS™ offers a treatment by an independent device that doesn't require any additional components during the procedure. The operation is rather intuitive and can be performed by one surgeon or GI. In addition, the procedure can be conducted in the endoscopy suite to ensure the saving of operation room time.

Dr. Elazar Sonnenschein, Medigus CEO commented: "Medigus has developed an innovative solution to treat GERD and we're excited to present the excellent supportive data from our three year study and five-year follow-up. It is rewarding to watch patients that no longer need to rely on daily use of drugs to support their routine. We strongly believe that our minimal invasive solution will replace many of the unnecessary surgeries which are performed today."

The Digestive Disease Week (DDW) is the largest and most prestigious conference in the world for the Gastrointestinal Infection (GI) professional community and an average of 15,000 medical professionals from around the world attend this meeting every year.

About Medigus Ltd.

Medigus (TASE: MDGS) is a medical device company headquartered in Omer, Israel, specializing in developing innovative endoscopic procedures and devices. Medigus is a pioneer developer of a unique proprietary endoscopic device for the treatment of GERD, one of the most common chronic diseases in the western world.

Medigus has an advanced technology platform that includes all necessary elements for performing a wide range of endoscopic procedures. The platform includes various types of rigid, semi-flexible and flexible video endoscopes, as well as respective endoscopy suites.

For more information please visit: http://www.medigus.com    

Contact:
Miri Segal-Scharia
Hayden/ MS-IR LLC
Tel: +1-917-607-8654
[email protected]

SOURCE Medigus Ltd

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED